NCT05841238 is a Phase 1 clinical trial of LY3502970 in Healthy, sponsored by Eli Lilly and Company.

Who is sponsoring NCT05841238?

NCT05841238 is sponsored by Eli Lilly and Company.

What drugs are being tested in NCT05841238?

Interventions in NCT05841238: LY3502970.

What condition does NCT05841238 study?

NCT05841238 studies Healthy, Obese.

Is NCT05841238 still recruiting?

NCT05841238 is currently completed. Last updated 2 October 2024.

Last reviewed 2024-10-02 · How we verify

NCT05841238

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants

Completed Phase 1 Last updated 2 October 2024

What this trial tests

Phase 1 trial testing LY3502970 in Healthy in 52 participants. Completed in 13 November 2023.

Timeline

26 April 2023

Primary endpoint
14 September 2023

13 November 2023

Quick facts

Lead sponsor	Eli Lilly and Company
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	52
Start date	26 April 2023
Primary completion	14 September 2023
Estimated completion	13 November 2023
Sites	3 locations across United States

Drugs / interventions tested

LY3502970 — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →
Obese — all drugs for Obese →

Sponsor

Eli Lilly and Company — full company profile →

Who can join

Adults 18 to 70, any sex, with Healthy or Obese. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to evaluate how much LY3502970 gets into the bloodstream and how long it takes the body to eliminate when administered orally as tablet and capsule formulations along with effect of food on LY3502970 in healthy overweight and obese participants. The study will also evaluate the safety and tolerability of LY3502970 in these participants. The study is conducted in two parts (part A and B) and will last up to 135 days including the screening period.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.
Ma X, Li YG, Raha S, Sperry DC, et al · · 2026 · PMID 41994902 · DOI 10.1111/dom.70783

Verify or expand the search:

Other trials of LY3502970

Trials testing the same drug.

NCT06085482 — A Phase I Study of LY3502970 in Healthy Participants · Phase 1 · completed
NCT06023095 — A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities · Phase 1 · completed
NCT05936138 — A Study of LY3502970 in Participants With Normal and Impaired Renal Function · Phase 1 · completed
NCT05882032 — A Study of LY3502970 in Participants With Impaired and Normal Liver Function · Phase 1 · completed
NCT05573230 — A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants · Phase 1 · completed

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Eli Lilly and Company trials

Trials by the same sponsor.

NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05841238 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 2 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05841238.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing